Close Menu

NEW YORK – Co-Diagnostics said on Tuesday that it has entered into definitive agreements with institutional investors for the purchase of approximately 3.2 million shares of its common stock at a purchase price of $3.08 per share in a registered direct offering priced at the market.

The Salt Lake City, Utah-based molecular diagnostics developer said gross proceeds from the offering are expected to be approximately $10.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.